Candel Therapeutics (CADL) AI Stock Analysis

• Market Cap: $280.81M
• Dividend Yield: N/A
• Average Volume (3M): 1.35M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.73
• Revenue Growth: N/A
• EPS Growth: -33.79%
• Country: US
• Employees: 38
• Sector: Healthcare
• Sector Strength: 72
• Industry: Biotechnology
• EPS (TTM): -1.75
• Shares Outstanding: 47,235,460
• 10 Day Avg. Volume: 1,287,540
• 30 Day Avg. Volume: 1,349,464
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -16.40
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $21.00
• Price Target Upside: 253.54% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

Candel Therapeutics is facing critical financial challenges, with no revenue and ongoing cash burn. Despite positive trial results and a strong pipeline, the stock is under downward pressure. A negative P/E ratio and lack of dividend yield highlight investor caution. The company must leverage its clinical successes to improve financial health.

Positive Factors

Clinical Trial Results

Recent compelling phase 3 results in prostate cancer and encouraging phase 2 data in pancreatic and lung cancer strengthen the clinical profile of CAN-2409.

Market Potential

The potential peak sales of $1.1 billion for CAN-2409, across large markets like prostate, pancreatic, and lung cancer, indicate significant revenue opportunities.

Partnership and Commercial Strategy

The partnership with IDEA Pharma enhances the potential for quicker ramp to launch, higher peak penetration, and earlier launch/approval of CAN-2409.

Negative Factors

Financial Needs

The company is likely needing additional financing to support larger pivotal trials and potential filings beyond prostate cancer.

Funding Requirements

Candel Therapeutics may face challenges in securing the necessary funds to support the ambitious clinical and commercial plans for CAN-2409.

Candel Therapeutics Business Overview & Revenue Model

Company Description

Candel Therapeutics, Inc. (CADL) is a clinical-stage biopharmaceutical company focused on developing novel viral immunotherapies for the treatment of cancer. The company operates within the biotechnology and pharmaceutical sectors, leveraging its proprietary technology platforms to advance a pipeline of product candidates aimed at addressing unmet medical needs in oncology. Candel's core offerings include oncolytic viral immunotherapies designed to selectively target and destroy cancer cells while stimulating a systemic anti-tumor immune response.

How the Company Makes Money

Candel Therapeutics makes money primarily through the development and potential commercialization of its proprietary viral immunotherapy candidates. The company's revenue model is centered on advancing its product candidates through clinical trials to achieve regulatory approval, at which point they can be marketed and sold to healthcare providers and patients. Key revenue streams include potential milestone payments and royalties from licensing agreements with larger pharmaceutical companies, as well as potential future sales of approved therapies. Candel may also receive funding from partnerships and collaborations that support the research and development of its therapeutic candidates. However, as a clinical-stage company, current revenues may be limited, and the company often relies on raising capital through public or private offerings to fund its operations and ongoing research activities.

Candel Therapeutics Financial Statement Overview

Summary

Candel Therapeutics is facing significant financial challenges due to the lack of revenue and persistent cash burn, common in the biotech sector. While there are some improvements in balance sheet metrics, the negative cash flow and reliance on financing activities are concerning.

Income Statement

Candel Therapeutics has not generated any revenue for the latest year, which is a significant concern for any company, particularly in the biotechnology industry. The consistent lack of revenue growth and negative net income highlights ongoing financial challenges. The EBIT and EBITDA margins are negative, indicating operational inefficiencies and a lack of profitability.

Balance Sheet

The company's balance sheet shows a moderate debt-to-equity ratio, but this is somewhat misleading due to the lack of equity in recent years. The negative equity in previous years is concerning, though there has been improvement in the latest year. The equity ratio is unstable, suggesting financial vulnerability. The presence of cash and cash equivalents provides some liquidity cushion.

Cash Flow

The cash flow statement reveals negative operating and free cash flows, indicating cash burn, which is typical for biotech firms focused on R&D. However, the substantial negative free cash flow growth rate and reliance on financing activities to sustain operations pose significant financial risks.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
1.78M	0.00	0.00	125.00K	125.00K	125.00K
	Gross Profit
964.00K	0.00	-23.98M	-862.00K	-107.00K	125.00K
	EBIT
-35.55M	-33.37M	-38.39M	-34.72M	-25.73M	-13.81M
	EBITDA
-48.77M	-33.37M	-37.43M	-17.32M	-25.49M	-13.72M
	Net Income Common Stockholders
-52.20M	0.00	-37.94M	-2.87M	-36.18M	-22.17M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
45.06M	102.65M	35.41M	70.06M	82.64M	35.05M
	Total Assets
0.00	106.87M	41.20M	77.69M	89.20M	38.28M
	Total Debt
0.00	10.87M	22.76M	22.80M	560.00K	946.00K
	Net Debt
45.06M	-91.79M	-12.65M	-47.26M	-82.08M	-34.11M
	Total Liabilities
0.00	40.54M	28.46M	29.98M	25.07M	61.84M
	Stockholders Equity
41.02M	66.33M	12.74M	-99.09M	64.14M	-23.56M
Cash Flow		Free Cash Flow
-28.69M	-27.04M	-34.70M	-32.72M	-24.05M	-10.55M
	Operating Cash Flow
-28.63M	-27.02M	-34.24M	-31.42M	-22.22M	-9.07M
	Investing Cash Flow
-40.00K	-16.00K	-280.00K	-1.30M	-1.83M	38.45M
	Financing Cash Flow
2.25M	94.28M	-121.00K	19.97M	71.80M	490.00K

Candel Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.94
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CADL, the sentiment is Negative. The current price of 5.94 is below the 20-day moving average (MA) of 8.06, below the 50-day MA of 8.18, and below the 200-day MA of 6.73, indicating a bearish trend. The MACD of -0.36 indicates Positive momentum. The RSI at 32.02 is Neutral, neither overbought nor oversold. The STOCH value of 5.03 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CADL.

Candel Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BNTC	54 Neutral	$342.39M	―	-46.85%	―	-100.00%	72.73%
Sector *	49 Neutral	$6.85B	0.81	-52.91%	2.50%	17.48%	1.17%
AFMD	42 Neutral	$11.89M	―	-151.46%	―	-95.23%	-325.89%
CADL	41 Neutral	$280.81M	―	-139.56%	―	―	-33.79%
IMUX	34 Underperform	$108.09M	―	-216.24%	―	―	61.97%
ADXS	20 Underperform	$1.92M	―	197.20%	―	―	―

Candel Therapeutics Corporate Events

Candel Therapeutics Reports Positive Phase 2a Trial Results

On March 26, 2025, Candel Therapeutics announced positive final survival data from its phase 2a clinical trial of CAN-2409 in patients with stage III/IV non-small cell lung cancer (NSCLC) who were inadequately responding to immune checkpoint inhibitor (ICI) treatment. The trial results showed a median overall survival (mOS) of 24.5 months for patients with inadequate ICI response and 21.5 months for those with progressive disease, significantly exceeding the survival rates of 9.8–11.8 months reported in similar populations treated with standard chemotherapy. The data also highlighted a potential precision medicine approach, with non-squamous NSCLC patients showing improved survival rates and a systemic anti-tumor response. These findings suggest CAN-2409 may offer a new treatment avenue for NSCLC patients with limited options, and the company plans to advance its development program for this therapy.

Candel Therapeutics Reports Positive Phase 2 Trial Results

On February 25, 2025, Candel Therapeutics announced positive final overall survival data from its phase 2 clinical trial of CAN-2409 in non-metastatic pancreatic cancer. The trial showed that patients treated with CAN-2409 had a median overall survival of 31.4 months compared to 12.5 months in the control group, with a favorable safety profile. This data highlights the potential of CAN-2409 to significantly improve survival in pancreatic cancer, supporting its further development in a larger, late-stage trial.

Candel Therapeutics Highlights Pipeline Progress and Stability

Candel Therapeutics announced a corporate update highlighting strong pipeline momentum and key value drivers for 2025, including the reporting of updated overall survival data for CAN-2409 in pancreatic ductal adenocarcinoma and non-small cell lung cancer, and preparations for a Biologics License Application for CAN-2409 in prostate cancer. The company reported an unaudited cash position of $102.9 million as of December 31, 2024, sufficient to fund operations into Q1 2027, reflecting their financial stability and capacity to pursue ongoing and upcoming clinical trials and regulatory submissions.